

# EDOXYBAN AND DABIGATRAN DOSAGE: IS THE ESTIMATING CREATININE CLEARANCE FORMULA IMPORTANT?

A. RODRÍGUEZ ESQUÍROZ, O. GOÑI ZAMARBIDE, L. GARCÍA LÓPEZ, J. GORRICO MENDÍVIL, A. ECHEVERRÍA GORRITI, M. MARÍN MARÍN, J. FERNÁNDEZ GONZÁLEZ, L. SANZ ÁLVAREZ, J. GARJÓN PARRA  
Pharmacy and Services Sub-Directorate. Navarre Health Service (Spain); Contact data: (arodries@navarra.es)



## BACKGROUND AND IMPORTANCE

Edoxaban and dabigatran **product information** recommend using Cockcroft-Gault formula to estimate creatinine clearance ( $Cl_{CR}$ ) in order to make dose adjustments. However, our **medical records calculate**  $Cl_{CR}$  with CKD-EPI formula.

## AIM AND OBJECTIVES

To identify discrepancies between the recommended dose of edoxaban and dabigatran depending on the formula used to estimate  $Cl_{CR}$ .

Is anticoagulant dose based on CKD-EPI equals to dose based on Cockcroft-Gault



## MATERIALS AND METHODS

**Study design:** Cross-sectional observational study.

**Inclusion criteria:** Adults treated with edoxaban or dabigatran for atrial fibrillation (AF) in July 2025.


**Exclusion criteria:** a weight and/or serum creatinine (Scr) record before August 2024, patients treated with edoxaban weighting  $\leq 60$  kg or receiving concomitant treatment with P-glycoprotein inhibitors.

**Collected data:** age, sex, weight, Scr,  $Cl_{CR}$  according to CKD-EPI and Cockcroft-Gault formulas, dialysis and concomitant treatment with cyclosporine, dronedarone, erythromycin or ketoconazole.

Dose differences classification:

- For EDOXYBAN: underdose, overdose or should be contraindicated
- For DABIGATRAN: should be contraindicated

## RESULTS



**Contraindication recommendations did not varied regardless of the formula used with edoxaban or dabigatran**

## CONCLUSION AND RELEVANCE

Using CKD-EPI formula instead of Cockcroft-Gault, 11.1% patients treated with edoxaban for AF would be over (2/3) or under-dosed (1/3) according to the estimating formula.

**No contraindication recommendation differences were found in patients treated with dabigatran or edoxaban.**

It would be advisable for regulatory agencies to issue clear recommendations on dosing with the available estimation formulas.

